HomeTagsEosinophilic Esophagitis

Eosinophilic Esophagitis

Healthcare

Dupixent Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis

PR Newswire - July 15, 2022

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that a Phase 3 trial assessing the investigational use of Dupixent (dupilumab) in children aged 1 to...

Biotechnology

FDA Accepts Dupixent for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis

PR Newswire - April 5, 2022

Regeneron Pharmaceuticals, Inc. and Sanofi announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA)...